Delay in EUGMP audit
If the EUGMP audit is delayed beyond Q1 FY27, regulated market entry and NIP revenue inflection could be pushed out further.
ZIMLABORATORIES / bear-case history
Track the concerns that keep returning.
Zim Laboratories · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
Preferential issue pricing concerns
Analysts questioned the preferential issue at a low price, raising concerns about dilution and fair value.
Dependence on a single strategic investor
The company relied on one investor for the preferential issue, which may create concentration risk.
Margin pressure from regulatory investments
Continued spending on CAPA and compliance initiatives may keep margins under pressure until regulated market revenue materializes.